Propylene Glycol

Propylene Glycol

SCHEMBL156298

C[C@H](O)CO.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Propylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3315124-B1 BILAYER TABLET FORMULATIONS ASTRAZENECA AB (SE) 2021-01-06 EP claimed
EP-2670397-B1 PHARMACEUTICAL FORMULATIONS INCLUDING AN AMINE COMPOUND BRISTOL MYERS SQUIBB CO (US) 2020-05-13 EP claimed
CN-105193761-B Bilayer tablet 阿斯利康(瑞典)有限公司 2019-12-06 CN claimed
CN-108516966-A Crystal form of Dapagliflozin and its preparation method and application 浙江海正药业股份有限公司 2018-09-11 CN claimed
WO-2018142422-A1 PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN INDOCO REMEDIES LIMITED (IN) 2018-08-09 WO claimed
EP-2498759-B1 IMMEDIATE RELEASE TABLET FORMULATIONS ASTRAZENECA AB (SE) 2018-08-01 EP claimed
EP-2498758-B1 BILAYER TABLET FORMULATIONS ASTRAZENECA AB (SE) 2018-07-25 EP claimed
EP-2611442-B1 DRUG FORMULATIONS USING WATER SOLUBLE ANTIOXIDANTS BRISTOL MYERS SQUIBB CO (US) 2018-07-04 EP claimed
EP-3315124-A1 BILAYER TABLET FORMULATIONS Astrazeneca AB (SE) 2018-05-02 EP claimed
US-20170333353-A1 BILAYER TABLET FORMULATIONS BRISTOL-MEYERS SQUIBB COMPANY 2017-11-23 US claimed
US-20130129819-A1 Pharmaceutical Formulations Containing An SGLT2 Inhibitor BRISTOL-MYERS SQUIBB COMPANY (US) 2013-05-23 US claimed
US-20130034606-A1 IMMEDIATE RELEASE TABLET FORMULATIONS ASTRAZENECA UK LIMITED (GB) 2013-02-07 US claimed
US-20120282336-A1 BILAYER TABLET FORMULATIONS ASTRAZENECA UK LIMITED (GB) 2012-11-08 US claimed
CN-102740839-A Immediate release tablet BRISTOL MYER SQUIBB COMPANY 2012-10-17 CN claimed
CN-102711739-A bilayer tablet BRISTOL MYERS SQUIBB CO 2012-10-03 CN claimed
EP-2498758-A2 BILAYER TABLET FORMULATIONS Bristol-Myers Squibb Company (US) 2012-09-19 EP claimed
EP-2498759-A2 IMMEDIATE RELEASE TABLET FORMULATIONS Bristol-Myers Squibb Company (US) 2012-09-19 EP claimed
WO-2012031124-A2 DRUG FORMULATIONS USING WATER SOLUBLE ANTIOXIDANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-08 WO claimed
WO-2011060290-A2 IMMEDIATE RELEASE TABLET FORMULATIONS Bristol-Myer Squibb Company (US) 2011-05-19 WO claimed
WO-2011060256-A2 BILAYER TABLET FORMULATIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO claimed